GlassScriptPhysician profile
Syed A Rasheed
NPI 1669511036
$3,921.96
in general payments reported to CMS, 2019-2025
25 companies · $34.60 in 2025
The $34.60 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $396 · 2021: $700 · 2022: $939 · 2023: $1,070 · 2024: $323 · 2025: $34.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $442.74 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $420.00 | 2022-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $344.56 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $340.77 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $311.39 | 2019-2024 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $260.92 | 2021-2024 | Austedo, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $231.11 | 2019-2023 | Trintellix |
| Abbvie INC. | $219.02 | 2021-2024 | |
| Neos Therapeutics, LP | $218.54 | 2019-2022 | |
| Alkermes, INC. | $179.56 | 2022-2025 | Lybalvi, Aristada |
| Bard Peripheral Vascular, INC. | $134.78 | 2022 | |
| Abbott Laboratories | $114.51 | 2022 | |
| Arbor Pharmaceuticals, INC. | $80.03 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $76.53 | 2022-2024 | Quviviq |
| Corium, LLC | $74.27 | 2022-2023 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $72.46 | 2023-2024 | Auvelity |
| Allergan, INC. | $72.44 | 2019-2020 | |
| Bausch Health US, LLC | $68.54 | 2019-2022 | |
| Orexo US, INC. | $64.31 | 2019-2021 | |
| Almatica Pharma LLC | $41.27 | 2022-2023 | Loreev Xr |
| Eisai INC. | $37.36 | 2020-2021 | |
| Sage Therapeutics, LLC | $31.22 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $30.94 | 2022-2023 | Spravato |
| Tris Pharma INC | $29.56 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $25.13 | 2020-2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rasheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.